IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in slowing rare kidney disease
Disease control OngoingThis study tests a new medicine called sparsentan for people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 400 adults with the condition took either sparsentan or a standard blood pressure drug for 2 years. The goal was to see if sparsentan better …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Apr 29, 2026 08:01 UTC
-
New hope for kidney disease: drug aims to cut protein leak and preserve function
Disease control OngoingThis phase 3 study tests an investigational drug called povetacicept in 605 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug reduces protein in the urine and slows the decline in kidney function compared to a placebo. P…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Apr 28, 2026 13:01 UTC